65
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Skeletal muscle PGC-1α1 modulates kynurenine metabolism and mediates resilience to stress-induced depression.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Depression is a debilitating condition with a profound impact on quality of life for millions of people worldwide. Physical exercise is used as a treatment strategy for many patients, but the mechanisms that underlie its beneficial effects remain unknown. Here, we describe a mechanism by which skeletal muscle PGC-1α1 induced by exercise training changes kynurenine metabolism and protects from stress-induced depression. Activation of the PGC-1α1-PPARα/δ pathway increases skeletal muscle expression of kynurenine aminotransferases, thus enhancing the conversion of kynurenine into kynurenic acid, a metabolite unable to cross the blood-brain barrier. Reducing plasma kynurenine protects the brain from stress-induced changes associated with depression and renders skeletal muscle-specific PGC-1α1 transgenic mice resistant to depression induced by chronic mild stress or direct kynurenine administration. This study opens therapeutic avenues for the treatment of depression by targeting the PGC-1α1-PPAR axis in skeletal muscle, without the need to cross the blood-brain barrier.

          Related collections

          Author and article information

          Journal
          Cell
          Cell
          Elsevier BV
          1097-4172
          0092-8674
          Sep 25 2014
          : 159
          : 1
          Affiliations
          [1 ] Department of Physiology and Pharmacology, Molecular and Cellular Exercise Physiology, Karolinska Institutet, 17177 Stockholm, Sweden.
          [2 ] Department of Physiology and Pharmacology, Molecular and Cellular Exercise Physiology, Karolinska Institutet, 17177 Stockholm, Sweden; Department of Neuroscience, Karolinska Institutet, 17177 Stockholm, Sweden.
          [3 ] Department of Physiology and Pharmacology, Neuropsychoimmunology, Karolinska Institutet, 17177 Stockholm, Sweden.
          [4 ] AstraZeneca R&D, Innovative Medicines, Personalized Healthcare and Biomarkers, Translational Science Center, Science for Life Laboratory, 17165 Solna, Sweden; Department of Clinical Neuroscience, Karolinska Institutet, 17177 Stockholm, Sweden.
          [5 ] Department of Physiology and Pharmacology, Integrative Physiology, Karolinska Institutet, 17177 Stockholm, Sweden.
          [6 ] Department of Physiology and Pharmacology, Integrative Physiology, Karolinska Institutet, 17177 Stockholm, Sweden; Department of Molecular Medicine and Surgery, Integrative Physiology, Karolinska Institutet, 17177 Stockholm, Sweden.
          [7 ] Department of Neuroscience, Karolinska Institutet, 17177 Stockholm, Sweden. Electronic address: mia.lindskog@ki.se.
          [8 ] Department of Physiology and Pharmacology, Molecular and Cellular Exercise Physiology, Karolinska Institutet, 17177 Stockholm, Sweden. Electronic address: jorge.ruas@ki.se.
          Article
          S0092-8674(14)01049-6
          10.1016/j.cell.2014.07.051
          25259918
          30158b6f-f022-49c6-a844-0b0bea1cf1ea
          Copyright © 2014 Elsevier Inc. All rights reserved.
          History

          Comments

          Comment on this article